» Articles » PMID: 2119883

Urokinase-plasminogen Activator, a New and Independent Prognostic Marker in Breast Cancer

Overview
Journal Cancer Res
Specialty Oncology
Date 1990 Nov 1
PMID 2119883
Citations 64
Authors
Affiliations
Soon will be listed here.
Abstract

Urokinase plasminogen activator (UK-PA) is a serine protease implicated in cancer invasion and metastasis. In this investigation, patients with breast cancers containing high levels of UK-PA antigen had significantly higher risk of early disease recurrence and shorter overall survival than did patients with low levels of the protein. In univariate analysis, UK-PA was a more powerful discriminator for disease-free interval than axillary node status, tumor size, or estradiol receptor. For overall survival, UK-PA as a prognostic marker, was of similar magnitude to axillary node status but stronger than that of tumor size or estradiol receptor. In multivariate analysis, for both disease-free interval and survival, UK-PA was an independent risk factor, being independent of tumor size, axillary node status, and estradiol receptor. UK-PA appears to be a new and independent prognostic marker in breast cancer.

Citing Articles

The Role of Fibrinolytic System in Health and Disease.

Kwaan H Int J Mol Sci. 2022; 23(9).

PMID: 35563651 PMC: 9101224. DOI: 10.3390/ijms23095262.


Targeting the Urokinase-Type Plasminogen Activator Receptor (uPAR) in Human Diseases With a View to Non-invasive Imaging and Therapeutic Intervention.

Leth J, Ploug M Front Cell Dev Biol. 2021; 9:732015.

PMID: 34490277 PMC: 8417595. DOI: 10.3389/fcell.2021.732015.


Exploring the Molecular Mechanism of the Drug-Treated Breast Cancer Based on Gene Expression Microarray.

Alshabi A, Shaikh I, Vastrad C Biomolecules. 2019; 9(7).

PMID: 31311202 PMC: 6681318. DOI: 10.3390/biom9070282.


uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies.

Duffy M, McGowan P, Harbeck N, Thomssen C, Schmitt M Breast Cancer Res. 2015; 16(4):428.

PMID: 25677449 PMC: 4423643. DOI: 10.1186/s13058-014-0428-4.


Targeting tumor cell invasion and dissemination in vivo by an aptamer that inhibits urokinase-type plasminogen activator through a novel multifunctional mechanism.

Botkjaer K, Deryugina E, Dupont D, Gardsvoll H, Bekes E, Thuesen C Mol Cancer Res. 2012; 10(12):1532-43.

PMID: 23038812 PMC: 3528818. DOI: 10.1158/1541-7786.MCR-12-0349.